Literature DB >> 20605699

Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome--comparison with other biomarkers.

Noriaki Kume1, Hirokazu Mitsuoka, Kazutaka Hayashida, Masaru Tanaka, Goro Kominami, Toru Kita.   

Abstract

BACKGROUND: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) appears to be involved in atherosclerotic plaque vulnerability and rupture. Circulating soluble LOX-1 (sLOX-1) levels are dramatically elevated in patients with acute coronary syndrome (ACS), and its diagnostic sensitivity and specificity is superior to high-sensitivity C-reactive protein (hs-CRP). In this study, we have compared the diagnostic value of sLOX-1 for ACS with those of troponin T (TnT) and heart-type fatty acid binding protein (H-FABP).
METHODS: One hundred and seven patients who underwent coronary angiography (CAG), including 18 ACS and 89 non-ACS patients were enrolled. Peripheral blood samples were obtained during the emergent or elective CAG. The non-ACS group consisted of 30 patients with normal CAG, 30 stable angina pectoris patients controlled by medical treatment, and 29 patients with stable angina who required elective coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft).
RESULTS: Age, gender, lipid profiles, or prevalence of diabetes, smoking, or hypertension were not significantly different between ACS and non-ACS. These factors did not significantly affect blood sLOX-1 levels. Circulating sLOX-1, TnT, and H-FABP levels were significantly higher in ACS than non-ACS. Area under the curve (AUC) values of the receiver-operating characteristic curves were 0.948, 0.704, and 0.691 for sLOX-1, TnT, and H-FABP, respectively. In a TnT-negative (<0.03 ng/mL) subgroup, the AUC values for sLOX-1 and H-FABP were 0.848 and 0.476, respectively.
CONCLUSION: Circulating sLOX-1 is a more sensitive and specific biomarker for ACS than TnT and H-FABP, and provides additional diagnostic values when measured in combination with TnT.
Copyright © 2010 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605699     DOI: 10.1016/j.jjcc.2010.05.002

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  25 in total

1.  Divergence of intracellular and extracellular HSP72 in type 2 diabetes: does fat matter?

Authors:  Josianne Rodrigues-Krause; Mauricio Krause; C O'Hagan; Giuseppe De Vito; Colin Boreham; Colin Murphy; Philip Newsholme; Gerard Colleran
Journal:  Cell Stress Chaperones       Date:  2012-01-04       Impact factor: 3.667

Review 2.  LOX-1, a new marker of risk and prognosis in coronary artery disease?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2013-08-11       Impact factor: 3.396

3.  CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme.

Authors:  Xue Qiang Zhao; Ming Wei Zhang; Fei Wang; Yu Xia Zhao; Jing Jing Li; Xu Ping Wang; Pei Li Bu; Jian Min Yang; Xiao Ling Liu; Ming Xiang Zhang; Fei Gao; Cheng Zhang; Yun Zhang
Journal:  J Lipid Res       Date:  2011-03-01       Impact factor: 5.922

4.  Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype.

Authors:  Will S Driscoll; Tomas Vaisar; Jingjing Tang; Carole L Wilson; Elaine W Raines
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

Review 5.  LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.

Authors:  Suowen Xu; Sayoko Ogura; Jiawei Chen; Peter J Little; Joel Moss; Peiqing Liu
Journal:  Cell Mol Life Sci       Date:  2012-11-03       Impact factor: 9.261

6.  Shedding light on impaired efferocytosis and nonresolving inflammation.

Authors:  Margaret L Novak; Edward B Thorp
Journal:  Circ Res       Date:  2013-06-21       Impact factor: 17.367

7.  Role of Plasma Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 and microRNA-98 in Severity and Risk of Coronary Artery Disease.

Authors:  Md Sayed Ali Sheikh
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

Review 8.  The discovery of LOX-1, its ligands and clinical significance.

Authors:  Ryo Yoshimoto; Yoshiko Fujita; Akemi Kakino; Shin Iwamoto; Tomohide Takaya; Tatsuya Sawamura
Journal:  Cardiovasc Drugs Ther       Date:  2011-10       Impact factor: 3.727

9.  Short-term exposure to air pollution and biomarkers of cardiovascular effect: A repeated measures study.

Authors:  Yu Ni; Russell P Tracy; Elaine Cornell; Joel D Kaufman; Adam A Szpiro; Matthew J Campen; Sverre Vedal
Journal:  Environ Pollut       Date:  2021-03-11       Impact factor: 9.988

Review 10.  Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.

Authors:  Jonathan De Siqueira; Izma Abdul Zani; David A Russell; Stephen B Wheatcroft; Sreenivasan Ponnambalam; Shervanthi Homer-Vanniasinkam
Journal:  J Cardiovasc Transl Res       Date:  2015-09-18       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.